Drug Profile
Egaptivon pegol
Alternative Names: ARC1779Latest Information Update: 12 Aug 2015
Price :
$50
*
At a glance
- Originator Archemix Corporation
- Class Antithrombotics; Nucleotide aptamers; Polyethylene glycols
- Mechanism of Action Von Willebrand factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haemolytic uraemic syndrome; Thrombosis; Thrombotic thrombocytopenic purpura; Von Willebrand disease
Most Recent Events
- 12 Feb 2010 A phase IIa trial in cerebral embolism discontinued because of slow enrolment
- 31 Mar 2009 Archemix initiates enrolment in a phase IIa trial for thrombosis prevention (in patients undergoing carotid endarterectomy) in Europe and North America
- 28 Jan 2009 Phase-II clinical trials in Haemolytic uraemic syndrome in Europe (IV)